Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peanut allergy immunotherapy - DBV Technologies

Next Previous
Drug Profile

Peanut allergy immunotherapy - DBV Technologies

Alternative Names: Current Viaskin peanut patch; cVP; DBV 712; EPIT®; Modified Viaskin peanut patch; mVP; Viaskin Peanut; ViaskinTM Peanut

Latest Information Update: 07 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DBV Technologies
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Peanut hypersensitivity

Most Recent Events

  • 24 Jun 2025 DBV Technologies initiates the phase III COMFORT Toddlers trial for Peanut hypersensitivity (In infants, In children) in USA (Topical) (NCT07003919)
  • 13 May 2025 DBV Technologies completed the phase III EPOPEX open-label extension trial in Peanut hypersensitivity (In children) in USA, Ireland, Netherlands, Germany, France and UK (Topical) (NCT03859700) (EUCT2018-003323-10)
  • 24 Mar 2025 DBV Technologies announces intention to submit BLA to US FDA for Peanut hypersensitivity (In children) in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top